BioXcel Therapeutics found using ticker (BTAI) now have 10 analysts in total covering the stock. The consensus rating is ‘Strong_Buy’. The range between the high target price and low target price is between 175 and 60 with a mean TP of 105.8. With the stocks previous close at 46.2 this is indicating there is a potential upside of 129.0%. The day 50 moving average is 47.81 and the 200 moving average now moves to 48.28. The market capitalisation for the company is $1,273m. Company Website: http://www.bioxceltherapeutics.com
BioXcel Therapeutics, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics has a collaboration with Merck KGaA; Nektar Therapeutics; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics is a subsidiary of BioXcel Corporation.